

10 September 2026

BSE Limited, Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai- 400001, India. Scrip Code: 544172	National Stock Exchange of India Limited Exchange Plaza, C-1, Block G, Bandra Kurla Complex, Bandra (E), Mumbai - 400 051, India. Trading symbol: INDGN
---	---

Dear Sir / Madam,

**Sub: Disclosure under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015
– Merger of Indirect Wholly Owned Subsidiaries.**

Pursuant to provisions of Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations"), we hereby inform that the merger of Indegene Healthcare Germany GmbH with Trilogy Writing & Consulting GmbH, both indirect wholly owned subsidiaries of Indegene Limited in Germany, was registered with the Commercial Register of the Local Court (Amtsgericht) of Frankfurt am Main on September 9, 2026.

Accordingly, the merger became effective on September 9, 2026. Consequent to the effectiveness of the merger, Indegene Healthcare Germany GmbH ceased to exist as a separate legal entity and Trilogy Writing & Consulting GmbH became the surviving entity.

Further, the change in the name of Trilogy Writing & Consulting GmbH to Indegene Healthcare Germany GmbH was also registered with the Commercial Register on September 9, 2026. Accordingly, the surviving entity shall hereafter operate under the name Indegene Healthcare Germany GmbH.

The aforesaid merger forms part of an internal reorganization of the Company's indirect wholly owned subsidiaries in Germany and does not have any material impact on the business operations, shareholding pattern, or financial position of Indegene Limited.

The detailed particulars required under Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025-CFD-POD2/1/3762/2026 dated January 30, 2026 are annexed to this letter.

The above information is being made available on the website of the Company <https://www.indegene.com/>

Kindly take the above-said information on record.

For Indegene Limited

Srishti Ramesh Kaushik
Company Secretary and Compliance Officer
 Encl: A/a



Indegene Limited

Third Floor, Aspen G-4 Block, Manyata Embassy
 Business Park (SEZ), Outer Ring Road, Nagawara, Bengaluru-
 560 045, Karnataka, India

Phone: +91 80 4674 4567, +91 80 4644 7777
 compliance.officer@indegene.com
 www.indegene.com

CIN: L73100KA1998PLC102040

Annexure – I

Disclosure of information pursuant to Regulation 30 of the Listing Regulations read with the SEBI Master Circular No. HO/49/14/14(7)2025–CFD–POD2/I/3762/2026 dated January 30, 2026.

Sl. No	Particulars	Details
1.	Name of the entity(ies) forming part of the amalgamation / merger, details in brief such as, size, turnover etc.	- Indegene Healthcare Germany GmbH (Transferor Company) - Trilogy Writing & Consulting GmbH (Transferee Company) Pursuant to the merger, the name of the surviving entity, Trilogy Writing & Consulting GmbH, has been changed to Indegene Healthcare Germany GmbH and it shall hereafter operate under that name. Projected revenue of Indegene Healthcare Germany GmbH for FY 2026–27: Euro 20,100,000
2.	Whether the transaction would fall within related party transactions? If yes, whether the same is done at “arm’s length”	Not Applicable
3.	Area of business of the entity(ies)	Indegene Healthcare Germany GmbH: Healthcare and life sciences services. Trilogy Writing & Consulting GmbH: Medical writing, regulatory, clinical and consulting services for the life sciences industry.
4.	Rationale for amalgamation / merger	Internal restructuring
5.	In case of cash consideration – amount or otherwise share exchange ratio.	Not applicable. The merger is an internal reorganization between indirect wholly owned subsidiaries of Indegene Limited and does not involve any cash consideration or share exchange.
6.	Brief details of change in shareholding pattern (if any) of listed entity	None